Amicus Therapeutics (Amicus Therapeutics) Interest Expense : $-50.1 Mil (TTM As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Amicus Therapeutics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Amicus Therapeutics's interest expense for the three months ended in Dec. 2023 was $ -12.8 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-50.1 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Amicus Therapeutics's Operating Income for the three months ended in Dec. 2023 was $ -3.7 Mil. Amicus Therapeutics's Interest Expense for the three months ended in Dec. 2023 was $ -12.8 Mil. Amicus Therapeutics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Amicus Therapeutics Interest Expense Historical Data

The historical data trend for Amicus Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amicus Therapeutics Interest Expense Chart

Amicus Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-18.87

-22.43

-32.47

-37.12

-50.15

Amicus Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-11.10	-11.84	-12.49	-12.99	-12.83

Amicus Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-50.1 Mil.

Amicus Therapeutics (NAS:FOLD) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Amicus Therapeutics's Interest Expense for the three months ended in Dec. 2023 was $-12.8 Mil. Its Operating Income for the three months ended in Dec. 2023 was $-3.7 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $436.7 Mil.

Amicus Therapeutics's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Amicus Therapeutics did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Amicus Therapeutics (Amicus Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amicus Therapeutics Inc (NAS:FOLD) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

AM6:Germany

Address

3675 Market Street, Philadelphia, PA, USA, 19104

Website

https://www.amicusrx.com

Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.

Executives

John F Crowley	director, officer: Executive Chairman	C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
David Michael Clark	officer: Chief People Officer	1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Samantha Prout	officer: Principal Accounting Officer	C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Bradley L Campbell	director, officer: President and CEO	C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Ellen Rosenberg	officer: General Counsel & Corp. Secy	C/O AMICUS THERAPEUTICS, 1 CEDAR BROOK DRIVE, CRANBURY NJ 08560
Jeff Castelli	officer: VP, Program Management	1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Harford Simon N.r.	officer: Chief Financial Officer	AVON PRODUCTS, INC., 1345 AVENUE OF THE AMERICAS, NEW YORK NY 10105
Michael Raab	director	1119 ST PAUL STREET, BALTIMORE MD 21202
Daphne Quimi	officer: Chief Financial Officer	C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Margaret G Mcglynn	director	C/O MERCK & CO INC, ONE MERCK DRIVE PO BOX 100, WHITEHOUSE STATION NJ 08889-0100
Burke W Whitman	director	13455 NOEL ROAD # 2000, DALLAS TX 75240
Eiry Roberts	director	C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEO CA 92130
Hung Do	officer: Sr Vice President Discovery	C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Michael Aaron Kelly	director	C/O HOOKIPA PHARMA INC., 430 EAST 29TH ST., NEW YORK NY 10016
Jay Barth	officer: Chief Medical Officer	C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512